Recent Insights » Whitepapers » Clinical event adjudication in cardiovascular device trials: An Food and Drug Administration perspective
×

Access Whitepaper

First Name
Last Name
Company
Thank you!
Error - something went wrong!
   

Clinical event adjudication in cardiovascular device trials: An Food and Drug Administration perspective

February 19, 2019

In this issue of the journal, Jonathan Seltzer presents an important review of the rationale and best practices for event adjudication in medical device clinical trials. The concepts presented in this work are well aligned with Food and Drug Administration's (FDA's) expectations for an adjudication process that enhances clinical study quality.

Previous Flipbook
Shifting the Tide of Inefficient Site Contract Negotiations: Turn to an Expert
Shifting the Tide of Inefficient Site Contract Negotiations: Turn to an Expert

Next Flipbook
Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing ev
Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing ev

This white paper provides a summary of presentations, discussions and conclusions of a Thinktank entitled “...

Request a Genetics in Clinical Trials training session

What You'll Learn
Return to Home